1. Waragai, M. and Ogawara, K. and Takaya, Y. and Hayashi, M. (1997) Efficacy of TRH‐T for spinocerebellar degeneration – the relation between clinical features and effect of TRH therapy. Rinsho Shinkeigaku, 37, pp. 587 - 94. [In Japanese]
2. Kanazawa, I. and Satoyoshi, E. and Hirayama, K. (1997) Clinical evaluation of taltirelin hydrate (TA‐0910) in patients with spinocerebellar degeneration –A multi‐center double‐blind comparative study with placebo. Rinsyo Iyaku, 13, pp. 4169 - 24. [In Japanese]
3. Fukuchi, I. and Asahi, T. and Kawashima, K. and Kawashima, Y. and Yamamura, M. and Matsuoka, Y. and Kinoshita, K. (1998) Effects of Taltirelin hydrate (TA‐0910), a novel thyrotropin‐releasing hormone analog, on in vivo dopamine release and turnover in rat brain. Arzneimittelforschung, 48, pp. 353 - 9.
4. Trouillas, P. (1990) L‐5‐Hydroxytryptophan treatment in cerebellar ataxia: Clinical and etiological correlations. Mov Disord, 5((Suppl. 1)), pp. 6.
5. Trouillas, P. and Brudon, F. and Adeleine, P. (1988) Improvement of cerebellar ataxia with levorotatory form of 5‐hydroxytryptophan. A double‐blind study with quantified data processing. Arch Neurol, 45, pp. 1217 - 22.